English Polski

Advanced search

Vol 22, No 3 (2016)
Guidelines / Expert consensus
Published online: 2017-02-10

open access

View PDF (Polish) Download PDF file
Page views 1284
Article views/downloads 12040
Get Citation

Connect on Social Media

Connect on Social Media

Wytyczne profilaktyki przeciwzakrzepowej u chorych onkologicznych, ze szczególnym uwzględnieniem pacjentów leczonych operacyjnie

Tomasz Urbanek, Zbigniew Krasiński, Maciej Kostrubiec, Wojciech Sydor, Piotr Wysocki, Artur Antoniewicz, Beata Begier-Krasińska, Wojciech Dyszkiewicz, Jan Kulig, Piotr Ładziński, Janina Markowska, Rodryg Ramlau, Piotr Rutkowski, Stefan Sajdak, Damian Ziaja, Krzysztof Ziaja
Acta Angiologica 2016;22(3):103-136.

Abstract

Żylna choroba zakrzepowo-zatorowa (ŻChZZ), mimo że często występuje na różnych etapach rozwoju procesu nowotworowego, stanowi ciągle niedoceniany problem w populacji chorych onkologicznych. Terapia przeciwnowotworowa, zabiegi operacyjne czy znacznego stopnia zaawansowanie choroby nowotworowej to tylko niektóre czynniki ryzyka ŻChZZ, stanowiącej nadal jedną z najczęstszych przyczyn zgonu w populacji pacjentów onkologicznych. Zróżnicowanie ryzyka wystąpienia zakrzepicy żył głębokich (ZŻG) oraz ryzyka powikłań, w tym powikłań krwotocznych, pomiędzy poszczególnymi grupami chorych onkologicznych sugeruje przeprowadzenie indywidualnej oceny ryzyka i postępowanie profilaktyczne zależne od sytuacji klinicznej konkretnego pacjenta. Uzasadnia to także stałą aktualizację wytycznych postępowania profilaktycznego proponowanego chorym onkologicznym. W dokumencie przedstawiono oparte na przeglądzie piśmiennictwa zasady postępowania profilaktycznego w populacji chorych onkologicznych, ze szczególnym uwzględnieniem profilaktyki przeciwzakrzepowej w dyscyplinach zabiegowych.

Keywords: żylna choroba zakrzepowo-zatorowachoroba nowotworowaleczenie chirurgiczne schorzeń onkologicznychprofilaktyka przeciwzakrzepowaterapia przeciwnowotworowa

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ. 2008; 336(7652): 1049–1051.
    CrossRef
  2. Guyatt GH, Oxman AD, Vist GE, et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650): 924–926.
    CrossRefPubMed
  3. Guyatt GH, Norris SL, Schulman S, et al. American College of Chest Physicians. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): 53S–70S.
    CrossRefPubMed
  4. Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013; 11(1): 56–70.
    CrossRefPubMed
  5. Debourdeau P, Farge D, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost. 2013; 11(1): 71–80.
    CrossRefPubMed
  6. Lyman GH, Bohlke K, Khorana AA, et al. American Society of Clinical Oncology, American Society of Clinical Oncology Clinical Practice, American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007; 25(34): 5490–5505.
    CrossRefPubMed
  7. Lyman G, Kuderer N. Prevention and treatment of venous thromboembolism among patients with cancer: The American Society of Clinical Oncology Guidelines. Thrombosis Research. 2010; 125: S120–S127.
    CrossRef
  8. Lyman GH, Bohlke K, Falanga A, et al. American Society of Clinical Oncology, American Society of Clinical Oncology, American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013; 31(17): 2189–2204.
    CrossRefPubMed
  9. Lyman GH, Bohlke K, Khorana AA, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. J Clin Oncol. 2015; 33: 654–656.
  10. Mandalà M, Falanga A, Roila F, et al. ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011; 22 Suppl 6: vi85–vi92.
    CrossRefPubMed
  11. Streiff MB. National Comprehensive Cancer Center Network. The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients. Thromb Res. 2010; 125 Suppl 2: S128–S133.
    CrossRefPubMed
  12. Streiff M, Bockenstedt P, Cataland S, et al. Venous Thromboembolic Disease. Journal of the National Comprehensive Cancer Network. 2013; 11(11): 1402–1429.
    CrossRef
  13. Kahn SR, Lim W, Dunn AS, et al. American College of Chest Physicians. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): e195S–e226S.
    CrossRefPubMed
  14. Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): e227S–277S.
  15. Zawilska K, Bała MM, Błędowski P, et al. Working Group fom the Anticoagulation and Thrombolytic ACCP Conference. [Polish guidelines for the prevention and treatment of venous thromboembolism. 2012 update]. Pol Arch Med Wewn. 2012; 122 Suppl 2: 3–74.
    PubMed
  16. Tomkowski W, Zawilska K, Chęciński P, et al. Profilaktyka i leczenie żylnej choroby zakrzepowo-zatorowej: „Konsensus polski” — aktualizacja 2011. Acta Angiol. 2011; 17: Suplement.
  17. Fijałkowska A, Szawłowski A, Wojtukiewicz M, et al. Rekomendacje Polskiego Towarzystwa Chirurgii Onkologicznej: Profilaktyka i przeciwzakrzepowe leczenie u pacjentów z nowotworami złośliwymi. Nowotwory. 2008; 1: 78–81.
  18. Mandalà M, Falanga A, Piccioli A, et al. working group AIOM. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol. 2006; 59(3): 194–204.
    CrossRefPubMed
  19. Farge D, Bosquet L, Kassab-Chahmi D, et al. SOR. 2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group. Crit Rev Oncol Hematol. 2010; 73(1): 31–46.
    CrossRefPubMed
  20. Debourdeau P, Kassab Chahmi D, Le Gal G, et al. Working group of the SOR, French National Feberation of Cancer Centers. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Oncol. 2009; 20(9): 1459–1471.
    CrossRefPubMed
  21. NICE guidance: Venous thromboembolism: reducing the risk: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital [CG92]. https://www.nice.org.uk/guidance/cg92.
  22. Konstantinides SV, Torbicki A, Agnelli G, et al. Authors/Task Force Members, Authors/Task Force Members, Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014; 35(43): 3033–3069.
    CrossRefPubMed
  23. Nicolaides AN, Fareed J, Kakkar AK, et al. Prevention and treatment of venous thromboembolism — International Consensus Statement. Int Angiol. 2013; 32: 111–260.
  24. Di Nisio M, Lee AYY, Carrier M, et al. Subcommittee on Haemostasis and Malignancy. Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2015; 13(5): 880–883.
    CrossRefPubMed
  25. Khorana AA, Otten HM, Zwicker JI, et al. Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH. J Thromb Haemost. 2014; 12(11): 1928–1931.
    CrossRefPubMed
  26. Di Nisio M, Carrier M, Lyman GH, et al. Subcommittee on Haemostasis and Malignancy. Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2014; 12(10): 1746–1749.
    CrossRefPubMed
  27. Zwicker JI, Connolly G, Carrier M, et al. Catheter-associated deep vein thrombosis of the upper extremity in cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2014; 12(5): 796–800.
    CrossRefPubMed
  28. Easaw JC, Shea-Budgell MA, Wu CMJ, et al. Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis. Curr Oncol. 2015; 22(2): 133–143.
    CrossRefPubMed
  29. Easaw JC, Shea-Budgell MA, Wu CMJ, et al. Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment. Curr Oncol. 2015; 22(2): 144–155.
    CrossRefPubMed
  30. Streiff MB, Holmstrom B, Ashrani A, et al. Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. J Natl Compr Canc Netw. 2015; 13(9): 1079–1095.
    PubMed
  31. Watson HG, Keeling DM, Laffan M, et al. British Committee for Standards in Haematology. Guideline on aspects of cancer-related venous thrombosis. Br J Haematol. 2015; 170(5): 640–648.
    CrossRefPubMed
  32. Elyamany G, Alzahrani AM, Bukhary E. Cancer-associated thrombosis: an overview. Clin Med Insights Oncol. 2014; 8: 129–137.
    CrossRefPubMed
  33. Akl EA, Muti P, Schünemann HJ. Anticoagulation in patients with cancer: an overview of reviews. Pol Arch Med Wewn. 2008; 118(4): 183–193.
    PubMed
  34. Kakkar VV, Howe CT, Nicolaides AN, et al. Deep vein thrombosis of the leg. Is there a "high risk" group? Am J Surg. 1970; 120(4): 527–530.
    PubMed
  35. Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev. 1992; 11(3-4): 237–248.
    PubMed
  36. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015; 12(8): 464–474.
    CrossRefPubMed
  37. Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007; 44(2): 62–69.
    CrossRefPubMed
  38. Wun T, White R. Venous Thromboembolism (VTE) in Patients with Cancer: Epidemiology and Risk Factors. Cancer Investigation. 2009; 27(sup1): 63–74.
    CrossRef
  39. Pellino G, Sciaudone G, Candilio G, et al. Predictors of Venous Thromboembolism after Colorectal Surgery in a Single Unit. Acta Chir Belg. 2015; 115(4): 288–292.
    PubMed
  40. Kucher N, Spirk D, Baumgartner I, et al. Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER). Ann Oncol. 2010; 21(5): 931–935.
    CrossRefPubMed
  41. Lyman G. Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. Cancer. 2009; 115(24): 5637–5650.
    CrossRef
  42. Agnelli G, Caprini JA. The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: emerging options. J Surg Oncol. 2007; 96(3): 265–272.
    CrossRefPubMed
  43. Danilenko-Dixon DR, Heit JA, Silverstein MD, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000; 160(6): 809–815.
    PubMed
  44. Nijziel MR, van Oerle R, Hillen HFP, et al. From Trousseau to angiogenesis: the link between the haemostatic system and cancer. Neth J Med. 2006; 64(11): 403–410.
    PubMed
  45. Caprini JA, Arcelus JI, Hasty JH, et al. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost. 1991; 17 Suppl 3: 304–312.
    PubMed
  46. Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon. 2005; 51(2-3): 70–78.
    CrossRefPubMed
  47. Ay C, Pabinger I. VTE risk assessment in cancer. Who needs prophylaxis and who does not? Hamostaseologie. 2015; 35(4): 319–324.
    CrossRefPubMed
  48. Bouras G, Burns EM, Howell AM, et al. Risk of Post-Discharge Venous Thromboembolism and Associated Mortality in General Surgery: A Population-Based Cohort Study Using Linked Hospital and Primary Care Data in England. PLoS One. 2015; 10(12): e0145759.
    CrossRefPubMed
  49. Törngren S, Rieger A. Prophylaxis of deep venous thrombosis in colorectal surgery. Dis Colon Rectum. 1982; 25(6): 563–566.
    PubMed
  50. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 Suppl): 338S–400S.
    CrossRefPubMed
  51. Danilenko-Dixon DR, Heit JA, Silverstein MD, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000; 160(6): 809–815.
    PubMed
  52. Merkow RP, Bilimoria KY, McCarter MD, et al. Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg. 2011; 254(1): 131–137.
    CrossRefPubMed
  53. Alsubaie H, Leggett C, Lambert P, et al. Diagnosis of VTE postdischarge for major abdominal and pelvic oncologic surgery: implications for a change in practice. Can J Surg. 2015; 58(5): 305–311.
    PubMed
  54. Larsen AC, Frøkjær JB, Fisker RV, et al. Treatment-related frequency of venous thrombosis in lower esophageal, gastro-esophageal and gastric cancer--a clinical prospective study of outcome and prognostic factors. Thromb Res. 2015; 135(5): 802–808.
    CrossRefPubMed
  55. Lodders JN, Parmar S, Stienen NLM, et al. Incidence of symptomatic venous thromboembolism in oncological oral and maxillofacial operations: retrospective analysis. Br J Oral Maxillofac Surg. 2015; 53(3): 244–250.
    CrossRefPubMed
  56. Chiesa Estomba C, Rivera Schmitz T, Ossa Echeverri CC, et al. The risk of venous thromboembolism in ENT and head & neck surgery. Otolaryngol Pol. 2015; 69(3): 31–36.
    CrossRefPubMed
  57. Kakei Y, Akashi M, Hasegawa T, et al. Incidence of Venous Thromboembolism After Oral Oncologic Surgery With Simultaneous Reconstruction. J Oral Maxillofac Surg. 2016; 74(1): 212–217.
    CrossRefPubMed
  58. Tran BH, Nguyen TJ, Hwang BH, et al. Risk factors associated with venous thromboembolism in 49,028 mastectomy patients. Breast. 2013; 22(4): 444–448.
    CrossRefPubMed
  59. De Martino RR, Goodney PP, Spangler EL, et al. Variation in thromboembolic complications among patients undergoing commonly performed cancer operations. J Vasc Surg. 2012; 55(4): 1035–1040.e4.
    CrossRefPubMed
  60. Lovely JK, Nehring SA, Boughey JC, et al. Balancing venous thromboembolism and hematoma after breast surgery. Ann Surg Oncol. 2012; 19(10): 3230–3235.
    CrossRefPubMed
  61. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg. 1988; 208(2): 227–240.
    PubMed
  62. Wille-Jørgensen P, Kjaergaard J. Prophylaxis of postoperative deep venous thrombosis. JAMA. 1985; 253(8): 1120.
    PubMed
  63. Bergqvist D, Burmark US, Frisell J, et al. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg. 1986; 73(3): 204–208.
    PubMed
  64. Bergqvist D, Mätzsch T, Burmark US, et al. Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. Br J Surg. 1988; 75(9): 888–891.
    PubMed
  65. Samama M, Bernard P, Bonnardot JP, et al. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg. 1988; 75(2): 128–131.
    PubMed
  66. Liezorovicz A, Picolet H, Peyrieux JC, et al. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. H.B.P.M. Research Group. Br J Surg. 1991; 78(4): 412–416.
    PubMed
  67. Boneu B. An international multicentre study: Clivarin in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the International Clivarin Assessment Group. Blood Coagul Fibrinolysis. 1993; 4 Suppl 1: S21–S22.
    PubMed
  68. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg. 1997; 84(8): 1099–1103.
    PubMed
  69. Kakkar VV, Cohen AT, Edmonson RA, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group. Lancet. 1993; 341(8840): 259–265.
    PubMed
  70. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. The European Fraxiparin Study (EFS) Group. Br J Surg. 1988; 75(11): 1058–1063.
    PubMed
  71. Baykal C, Al A, Demirtaş E, et al. Comparison of enoxaparin and standard heparin in gynaecologic oncologic surgery: a randomised prospective double-blind clinical study. Eur J Gynaecol Oncol. 2001; 22(2): 127–130.
    PubMed
  72. Akl EA, Kahale L, Sperati F, et al. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. Cochrane Database Syst Rev. 2014(6): CD009447.
    CrossRefPubMed
  73. Daniš J, Bergqvist D. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500versus 5000 XaI units in 2070 patients. British Journal of Surgery. 1995; 82(9): 1283–1284.
    CrossRef
  74. Kakkar AK, Agnelli G, George D et al (2011) The ultra-low-molecular-weight heparin semuloparin for prevention of venous thromboembolism in patients undergoing major abdominal surgery. Presented at the 53rd Annual Meeting of the American Society of Hematology San Diego, 10-13.12.2011.
  75. Simonneau G, Laporte S, Mismetti P, et al. FX140 Study Investigators. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. J Thromb Haemost. 2006; 4(8): 1693–1700.
    CrossRefPubMed
  76. Agnelli G, Bergqvist D, Cohen AT, et al. PEGASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg. 2005; 92(10): 1212–1220.
    CrossRefPubMed
  77. Yamaoka Y, Ikeda M, Ikenaga M, et al. Safety and efficacy of fondaparinux for prophylaxis of venous thromboembolism after colorectal cancer resection: a propensity score matched analysis. Dig Surg. 2015; 32(3): 190–195.
    CrossRefPubMed
  78. Bergqvist D, Agnelli G, Cohen AT, et al. ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002; 346(13): 975–980.
    CrossRefPubMed
  79. Rasmussen MS, Jorgensen LN, Wille-Jørgensen P, et al. FAME Investigators. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost. 2006; 4(11): 2384–2390.
    CrossRefPubMed
  80. Lausen I, Jensen R, Jorgensen LN, et al. Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. Eur J Surg. 1998; 164(9): 657–663.
    CrossRefPubMed
  81. Kakkar VV, Balibrea JL, Martínez-González J, et al. CANBESURE Study Group. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost. 2010; 8(6): 1223–1229.
    CrossRefPubMed
  82. Akl EA, Terrenato I, Barba M, et al. Extended perioperative thromboprophylaxis in patients with cancer. A systematic review. Thromb Haemost. 2008; 100(6): 1176–1180.
    PubMed
  83. Sakon M, Kobayashi T, Shimazui T. Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study. Thromb Res. 2010; 125(3): e65–e70.
    CrossRefPubMed
  84. Nagata C, Tanabe H, Takakura S, et al. Randomized controlled trial of enoxaparin versus intermittent pneumatic compression for venous thromboembolism prevention in Japanese surgical patients with gynecologic malignancy. J Obstet Gynaecol Res. 2015; 41(9): 1440–1448.
    CrossRefPubMed
  85. Song KY, Yoo HMo, Kim EY, et al. Optimal prophylactic method of venous thromboembolism for gastrectomy in Korean patients: an interim analysis of prospective randomized trial. Ann Surg Oncol. 2014; 21(13): 4232–4238.
    CrossRefPubMed
  86. Wang Jp, Lin Yd, Wang L, et al. [Effect of intermittent pneumatic compression on coagulation function and deep venous hemodynamics of lower limbs after rectal cancer resection]. Zhonghua Wei Chang Wai Ke Za Zhi. 2013; 16(8): 739–743.
    PubMed
  87. Ramirez JI, Vassiliu P, Gonzalez-Ruiz C, et al. Sequential compression devices as prophylaxis for venous thromboembolism in high-risk colorectal surgery patients: reconsidering American Society of Colorectal Surgeons parameters. Am Surg. 2003; 69(11): 941–945.
    PubMed
  88. Zareba P, Wu C, Agzarian J, et al. Meta-analysis of randomized trials comparing combined compression and anticoagulation with either modality alone for prevention of venous thromboembolism after surgery. Br J Surg. 2014; 101(9): 1053–1062.
    CrossRefPubMed
  89. Yasui M, Ikeda M, Miyake M, et al. Clinical Study Group of Osaka University (CSGO), Colorectal Group. Comparison of bleeding risks related to venous thromboembolism prophylaxis in laparoscopic vs open colorectal cancer surgery: a multicenter study in Japanese patients. Am J Surg. 2017; 213(1): 43–49.
    CrossRefPubMed
  90. Kimura Y, Oki E, Ando K, et al. Incidence of Venous Thromboembolism Following Laparoscopic Surgery for Gastrointestinal Cancer: A Single-Center, Prospective Cohort Study. World J Surg. 2016; 40(2): 309–314.
    CrossRefPubMed
  91. Xie YZ, Fang K, Ma WL, et al. Risk of postoperative deep venous thrombosis in patients with colorectal cancer treated with open or laparoscopic colorectal surgery: a meta-analysis. Indian J Cancer. 2015; 51 Suppl 2: e42–e44.
    CrossRefPubMed
  92. Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Guidelines Committee. Guidelines for deep venous thrombosis prophylaxis during laparoscopic surgery. Surg Endosc. 2007; 21(6): 1007–1009.
    CrossRefPubMed
  93. Vedovati MC, Becattini C, Rondelli F, et al. A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Ann Surg. 2014; 259(4): 665–669.
    CrossRefPubMed
  94. Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007; 110(10): 2339–2346.
    CrossRefPubMed
  95. Vitale C, D'Amato M, Calabrò P, et al. Venous thromboembolism and lung cancer: a review. Multidiscip Respir Med. 2015; 10(1): 28.
    CrossRefPubMed
  96. Zhang Y, Yang Y, Chen W, et al. China Venous Thromboembolism VTE Study Group, China Venous Thromboembolism (VTE) Study Group. Prevalence and associations of VTE in patients with newly diagnosed lung cancer. Chest. 2014; 146(3): 650–658.
    CrossRefPubMed
  97. Steuer CE, Behera M, Kim S, et al. Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis. Lung Cancer. 2015; 88(1): 80–84.
    CrossRefPubMed
  98. Dentali F, Malato A, Ageno W, et al. Incidence of venous thromboembolism in patients undergoing thoracotomy for lung cancer. J Thorac Cardiovasc Surg. 2008; 135(3): 705–706.
    CrossRefPubMed
  99. Kalweit G, Huwer H, Volkmer I, et al. Pulmonary embolism: a frequent cause of acute fatality after lung resection. Eur J Cardiothorac Surg. 1996; 10(4): 242–247.
    PubMed
  100. White RH, Zhou H, Gage BF, et al. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003; 90(3): 446–455.
    CrossRefPubMed
  101. Mason DP, Quader MA, Blackstone EH, et al. Thromboembolism after pneumonectomy for malignancy: an independent marker of poor outcome. J Thorac Cardiovasc Surg. 2006; 131(3): 711–718.
    CrossRefPubMed
  102. Weder W, Collaud S, Eberhardt WEE, et al. Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. J Thorac Cardiovasc Surg. 2010; 139(6): 1424–1430.
    CrossRefPubMed
  103. Hachey KJ, Hewes PD, Porter LP, et al. Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer. J Thorac Cardiovasc Surg. 2016; 151(1): 37–44.
    CrossRefPubMed
  104. Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg. 2004; 128(1): 138–146.
    CrossRefPubMed
  105. Christensen TD, Vad H, Pedersen S, et al. Venous thromboembolism in patients undergoing operations for lung cancer: a systematic review. Ann Thorac Surg. 2014; 97(2): 394–400.
    CrossRefPubMed
  106. Gómez-Hernández MT, Rodríguez-Pérez M, Novoa-Valentín N, et al. Prevalence of venous thromboembolism in elective thoracic surgery. Arch Bronconeumol. 2013; 49(7): 272–302.
    CrossRefPubMed
  107. Swiniarska J, Zekanowska E, Dancewicz M, et al. Pneumonectomy due to lung cancer results in a more pronounced activation of coagulation system than lobectomy. Eur J Cardiothorac Surg. 2009; 36(6): 1064–1068.
    CrossRefPubMed
  108. Yang Yi, Zhou Z, Niu XM, et al. Clinical analysis of postoperative venous thromboembolism risk factors in lung cancer patients. J Surg Oncol. 2012; 106(6): 736–741.
    CrossRefPubMed
  109. Kadlec B, Skrickova J, Merta Z, et al. The incidence and predictors of thromboembolic events in patients with lung cancer. ScientificWorldJournal. 2014: 125706.
    CrossRefPubMed
  110. Ziomek S, Read RC, Tobler HG, et al. Thromboembolism in patients undergoing thoracotomy. Ann Thorac Surg. 1993; 56(2): 223–227.
    PubMed
  111. Ljungström KG. Deep-vein thrombosis after major non-cardiovascular thoracic surgery. Scand J Thorac Cardiovasc Surg. 1985; 19(2): 161–164.
    PubMed
  112. Daddi G, Milillo G, Lupattelli L, et al. Pulmonary Embolism in Thoracic Surgery Study Group. Postoperative pulmonary embolism detected with multislice computed tomography in lung surgery for cancer. J Thorac Cardiovasc Surg. 2006; 132(1): 197–198.
    CrossRefPubMed
  113. Nagahiro I, Andou A, Aoe M, et al. Intermittent pneumatic compression is effective in preventing symptomatic pulmonary embolism after thoracic surgery. Surg Today. 2004; 34(1): 6–10.
    CrossRefPubMed
  114. Geerts WH, Bergqvist D, Pineo GF, et al. American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 Suppl): 381S–453S.
    CrossRefPubMed
  115. Detterbeck FC. Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician. WB Saunders, Philadelphia 2001.
  116. Cade JF, Clegg EA, Westlake GW. Prophylaxis of venous thrombosis after major thoracic surgery. Aust N Z J Surg. 1983; 53(4): 301–304.
    PubMed
  117. Azorin JF, Regnard JF, Dahan M, et al. [Efficacy and tolerability of fraxiparine in the prevention of thromboembolic complications in oncologic thoracic surgery]. Ann Cardiol Angeiol (Paris). 1997; 46(5-6): 341–347.
    PubMed
  118. Di Nisio M, Peinemann F, Porreca E, et al. Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery. Cochrane Database Syst Rev. 2015(6): CD009658.
    CrossRefPubMed
  119. Rahn DD, Mamik MM, Sanses TVD, et al. Society of Gynecologic Surgeons Systematic Review Group. Venous thromboembolism prophylaxis in gynecologic surgery: a systematic review. Obstet Gynecol. 2011; 118(5): 1111–1125.
    CrossRefPubMed
  120. Morimoto A, Ueda Y, Yokoi T, et al. Perioperative venous thromboembolism in patients with gynecological malignancies: a lesson from four years of recent clinical experience. Anticancer Res. 2014; 34(7): 3589–3595.
    PubMed
  121. Tateo S, Mereu L, Salamano S, et al. Ovarian cancer and venous thromboembolic risk. Gynecol Oncol. 2005; 99(1): 119–125.
    CrossRefPubMed
  122. Abu Saadeh F, Norris L, O'Toole S, et al. Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival. Eur J Obstet Gynecol Reprod Biol. 2013; 170(1): 214–218.
    CrossRefPubMed
  123. Morimoto A, Ueda Y, Yokoi T, et al. Perioperative venous thromboembolism in patients with gynecological malignancies: a lesson from four years of recent clinical experience. Anticancer Res. 2014; 34(7): 3589–3595.
    PubMed
  124. Peedicayil A, Weaver A, Li X, et al. Incidence and timing of venous thromboembolism after surgery for gynecological cancer. Gynecol Oncol. 2011; 121(1): 64–69.
    CrossRefPubMed
  125. Oranratanaphan S, Termrungruanglert W, Khemapech N. Incidence and Clinical Characteristic of Venous Thromboembolism in Gynecologic Oncology Patients attending King Chulalongkorn Memorial Hospital over a 10 Year Period. Asian Pac J Cancer Prev. 2015; 16(15): 6705–6709.
    PubMed
  126. Heath OM, van Beekhuizen HJ, Nama V, et al. Venous thromboembolism at time of diagnosis of ovarian cancer: Survival differs in symptomatic and asymptomatic cases. Thromb Res. 2016; 137: 30–35.
    CrossRefPubMed
  127. Krasiński Z, Szpurek D, Staniszewski R, et al. The value of extended preoperative thromboprophylaxis with dalteparin in patients with ovarian cancer qualified to surgical treatment. Int Angiol. 2014; 33(4): 365–371.
    PubMed
  128. Clarke-Pearson DL, Abaid LN. Prevention of venous thromboembolic events after gynecologic surgery. Obstet Gynecol. 2012; 119(1): 155–167.
    CrossRefPubMed
  129. Heilmann L, Tempelhoff GF, Schneider D. State-of the-Art Review : Prevention of Thrombosis in Gynecologic Malignancy. Clinical and Applied Thrombosis/Hemostasis. 1998; 4(3): 153–159.
    CrossRef
  130. Ward B, Pradhan S. Comparison of low molecular weight heparin (Fragmin) with sodium heparin for prophylaxis against postoperative thrombosis in women undergoing major gynaecological surgery. Aust N Z J Obstet Gynaecol. 1998; 38(1): 91–92.
    PubMed
  131. Baykal C, Al A, Demirtaş E, et al. Comparison of enoxaparin and standard heparin in gynaecologic oncologic surgery: a randomised prospective double-blind clinical study. Eur J Gynaecol Oncol. 2001; 22(2): 127–130.
    PubMed
  132. Maxwell GL, Synan I, Dodge R, et al. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. Obstet Gynecol. 2001; 98(6): 989–995.
    PubMed
  133. Oates-Whitehead RM, D'Angelo A, Mol B, et al. Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. Cochrane Database Syst Rev. 2003(4): CD003679.
    CrossRefPubMed
  134. Baykal C, Al A, Demirtaş E, et al. Comparison of enoxaparin and standard heparin in gynaecologic oncologic surgery: a randomised prospective double-blind clinical study. Eur J Gynaecol Oncol. 2001; 22(2): 127–130.
    PubMed
  135. Fricker JP, Vergnes Y, Schach R, et al. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest. 1988; 18(6): 561–567.
    PubMed
  136. Heilmann L, Tempelhoff GF, Kirkpatrick C, et al. Comparison of Unfractionated Versus Low Molecular Weight Heparin for Deep Vein Thrombosis Prophylaxis During Breast and Pelvic Cancer Surgery: Efficacy, Safety, and Follow-up. Clinical and Applied Thrombosis/Hemostasis. 1998; 4(4): 268–273.
    CrossRef
  137. Bouchard-Fortier G, Geerts WH, Covens A, et al. Is venous thromboprophylaxis necessary in patients undergoing minimally invasive surgery for a gynecologic malignancy? Gynecol Oncol. 2014; 134(2): 228–232.
    CrossRefPubMed
  138. Ageno W, Manfredi E, Dentali F, et al. The incidence of venous thromboembolism following gynecologic laparoscopy: a multicenter, prospective cohort study. J Thromb Haemost. 2007; 5(3): 503–506.
    CrossRefPubMed
  139. Abu-Rustum NR, Chi DS, Sonoda Y, et al. Transperitoneal laparoscopic pelvic and para-aortic lymph node dissection using the argon-beam coagulator and monopolar instruments: an 8-year study and description of technique. Gynecol Oncol. 2003; 89(3): 504–513.
    PubMed
  140. Panici PB, Plotti F, Zullo MA, et al. Pelvic lymphadenectomy for cervical carcinoma: laparotomy extraperitoneal, transperitoneal or laparoscopic approach? A randomized study. Gynecol Oncol. 2006; 103(3): 859–864.
    CrossRefPubMed
  141. Einstein MH, Pritts EA, Hartenbach EM. Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review. Gynecol Oncol. 2007; 105(3): 813–819.
    CrossRefPubMed
  142. Clark-Pearson DL, DeLong E, Synan IS, et al. A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obstet Gynecol. 1990; 75(4): 684–689.
    PubMed
  143. Clarke-Pearson DL, Synan IS, Dodge R, et al. A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol. 1993; 168(4): 1146–1153.
    PubMed
  144. Stroud W, Whitworth JM, Miklic M, et al. Validation of a venous thromboembolism risk assessment model in gynecologic oncology. Gynecol Oncol. 2014; 134(1): 160–163.
    CrossRefPubMed
  145. Maxwell GL, Synan I, Dodge R, et al. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. Obstet Gynecol. 2001; 98(6): 989–995.
    PubMed
  146. Khaldi A, Helo N, Schneck MJ, et al. Venous thromboembolism: deep venous thrombosis and pulmonary embolism in a neurosurgical population. J Neurosurg. 2011; 114(1): 40–46.
    CrossRefPubMed
  147. Portillo J, de la Rocha IV, Font L, et al. RIETE Investigations. Venous thromboembolism in patients with glioblastoma multiforme: Findings of the RIETE registry. Thromb Res. 2015; 136(6): 1199–1203.
    CrossRefPubMed
  148. Streiff MB, Ye X, Kickler TS, et al. A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors. J Neurooncol. 2015; 124(2): 299–305.
    CrossRefPubMed
  149. Taillibert S, Taillandier L, Le Rhun E. Venous thrombosis in patients with high-grade glioma. Curr Opin Oncol. 2015; 27(6): 516–521.
    CrossRefPubMed
  150. Salmaggi A, Simonetti G, Trevisan E, et al. Perioperative thromboprophylaxis in patients with craniotomy for brain tumours: a systematic review. J Neurooncol. 2013; 113(2): 293–303.
    CrossRefPubMed
  151. Collen JF, Jackson JL, Shorr AF, et al. Prevention of venous thromboembolism in neurosurgery: a metaanalysis. Chest. 2008; 134(2): 237–249.
    CrossRefPubMed
  152. Hamilton MG, Yee WH, Hull RD, et al. Venous thromboembolism prophylaxis in patients undergoing cranial neurosurgery: a systematic review and meta-analysis. Neurosurgery. 2011; 68(3): 571–581.
    CrossRefPubMed
  153. Smith TR, Nanney AD, Lall RR, et al. Development of venous thromboembolism (VTE) in patients undergoing surgery for brain tumors: results from a single center over a 10 year period. J Clin Neurosci. 2015; 22(3): 519–525.
    CrossRefPubMed
  154. Smith TR, Lall RR, Graham RB, et al. Venous thromboembolism in high grade glioma among surgical patients: results from a single center over a 10 year period. J Neurooncol. 2014; 120(2): 347–352.
    CrossRefPubMed
  155. Brandes AA, Scelzi E, Salmistraro G, et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer. 1997; 33(10): 1592–1596.
    PubMed
  156. Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer. 2000; 89(3): 640–646.
    PubMed
  157. Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol. 1983; 13(3): 334–336.
    CrossRefPubMed
  158. Walsh DC, Kakkar AK. Thromboembolism in brain tumors. Curr Opin Pulm Med. 2001; 7(5): 326–331.
    PubMed
  159. Semrad TJ, O'Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007; 106(4): 601–608.
    CrossRefPubMed
  160. Jenkins EO, Schiff D, Mackman N, et al. Venous thromboembolism in malignant gliomas. J Thromb Haemost. 2010; 8(2): 221–227.
    CrossRefPubMed
  161. Yust-Katz S, Mandel JJ, Wu J, et al. Venous thromboembolism (VTE) and glioblastoma. J Neurooncol. 2015; 124(1): 87–94.
    CrossRefPubMed
  162. Chan AT, Atiemo A, Diran LK, et al. Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. J Thromb Thrombolysis. 1999; 8(2): 139–142.
    PubMed
  163. Simanek R, Vormittag R, Hassler M, et al. Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol. 2007; 9(2): 89–95.
    CrossRefPubMed
  164. Kimmell KT, Walter KA. Risk factors for venous thromboembolism in patients undergoing craniotomy for neoplastic disease. J Neurooncol. 2014; 120(3): 567–573.
    CrossRefPubMed
  165. Turpie AG, Gallus A, Beattie WS, et al. Prevention of venous thrombosis in patients with intracranial disease by intermittent pneumatic compression of the calf. Neurology. 1977; 27(5): 435–438.
    PubMed
  166. Skillman JJ, Collins RE, Coe NP, et al. Prevention of deep vein thrombosis in neurosurgical patients: a controlled, randomized trial of external pneumatic compression boots. Surgery. 1978; 83(3): 354–358.
    PubMed
  167. Bucci MN, Papadopoulos SM, Chen JC, et al. Mechanical prophylaxis of venous thrombosis in patients undergoing craniotomy: a randomized trial. Surg Neurol. 1989; 32(4): 285–288.
    PubMed
  168. Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med. 1998; 339(2): 80–85.
    CrossRefPubMed
  169. Turpie AG, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis in potential neurosurgical patients. A randomized trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control. Arch Intern Med. 1989; 149(3): 679–681.
    PubMed
  170. Wautrecht JC, Macquaire V, Vandesteene A, et al. Prevention of deep vein thrombosis in neurosurgical patients withbrain tumors: a controlled, randomized study comparing graded compression stockings alone and with intermittent sequential compression: correlation with pre- and post-operative fibrinolysis; preliminary results. Int Angiol. 1996; 15(suppl 1): 5–10.
  171. Sobieraj-Teague M, Hirsh J, Yip G, et al. Randomized controlled trial of a new portable calf compression device (Venowave) for prevention of venous thrombosis in high-risk neurosurgical patients. J Thromb Haemost. 2012; 10(2): 229–235.
    CrossRefPubMed
  172. Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch Intern Med. 2000; 160(15): 2327–2332.
    PubMed
  173. Dickinson LD, Miller LD, Patel CP, et al. Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery. 1998; 43(5): 1074–1081.
    PubMed
  174. Nurmohamed MT, van Riel AM, Henkens CM, et al. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost. 1996; 75(2): 233–238.
    PubMed
  175. Cerrato D, Ariano C, Fiacchino F. Deep vein thrombosis and low-dose heparin prophylaxis in neurosurgical patients. J Neurosurg. 1978; 49(3): 378–381.
    CrossRefPubMed
  176. Constantini S, Kanner A, Friedman A, et al. Safety of perioperative minidose heparin in patients undergoing brain tumor surgery: a prospective, randomized, double-blind study. J Neurosurg. 2001; 94(6): 918–921.
    CrossRefPubMed
  177. Goldhaber SZ, Dunn K, Gerhard-Herman M, et al. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest. 2002; 122(6): 1933–1937.
    PubMed
  178. Macdonald RL, Amidei C, Baron J, et al. Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy. Surg Neurol. 2003; 59(5): 363–372.
    PubMed
  179. Samama CM, Albaladejo P, Benhamou D, et al. Committee for Good Practice Standards of the French Society for Anaesthesiology and Intensive Care (SFAR). Venous thromboembolism prevention in surgery and obstetrics: clinical practice guidelines. Eur J Anaesthesiol. 2006; 23(2): 95–116.
    CrossRefPubMed
  180. Forrest JB, Clemens JQ, Finamore P, et al. American Urological Association. AUA Best Practice Statement for the prevention of deep vein thrombosis in patients undergoing urologic surgery. J Urol. 2009; 181(3): 1170–1177.
    CrossRefPubMed
  181. COLBY FH. The prevention of fatal pulmonary emboli after prostatectomy. J Urol. 1948; 59(5): 920–925.
    PubMed
  182. Gordon-Smith IC, Hickman JA, el-Masri SH. The effect of the fibrinolytic inhibitor epsilon-aminocaproic acid on the incidence of deep-vein thrombosis after prostatectomy. Br J Surg. 1972; 59(7): 599.
    PubMed
  183. Nicolaides AN, Field ES, Kakkar VV, et al. Prostatectomy and deep-vein thrombosis. Br J Surg. 1972; 59(6): 487–488.
    PubMed
  184. Thomas PJ, Nurse DE, Deliveliotis C, et al. Cystoprostatectomy and substitution cystoplasty for locally invasive bladder cancer. Br J Urol. 1992; 70(1): 40–42.
    PubMed
  185. Alberts BD, Woldu SL, Weinberg AC, et al. Venous thromboembolism after major urologic oncology surgery: a focus on the incidence and timing of thromboembolic events after 27,455 operations. Urology. 2014; 84(4): 799–806.
    CrossRefPubMed
  186. Potretzke AM, Wong KS, Shi F, et al. Highest risk of symptomatic venous thromboembolic events after radical cystectomy occurs in patients with obesity or nonurothelial cancers. Urol Ann. 2015; 7(3): 355–360.
    CrossRefPubMed
  187. VanDlac AA, Cowan NG, Chen Y, et al. Timing, incidence and risk factors for venous thromboembolism in patients undergoing radical cystectomy for malignancy: a case for extended duration pharmacological prophylaxis. J Urol. 2014; 191(4): 943–947.
    CrossRefPubMed
  188. Rosario DJ, Becker M, Anderson JB. The changing pattern of mortality and morbidity from radical cystectomy. BJU Int. 2000; 85(4): 427–430.
    PubMed
  189. James AC, Holt SK, Wright JL, et al. Burden and timing of venothrombolic events in patients younger than 65 years undergoing radical cystectomy for bladder cancer. Urol Oncol. 2014; 32(6): 815–819.
    CrossRefPubMed
  190. White RH, Zhou H, Gage BF, et al. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003; 90(3): 446–455.
    CrossRefPubMed
  191. Heinzer H, Hammerer P, Graefen M, et al. Thromboembolic complication rate after radical retropubic prostatectomy. Impact of routine ultrasonography for the detection of pelvic lymphoceles and hematomas. Eur Urol. 1998; 33(1): 86–90.
    PubMed
  192. Leibovitch I, Foster RS, Wass JL, et al. Color Doppler flow imaging for deep venous thrombosis screening in patients undergoing pelvic lymphadenectomy and radical retropubic prostatectomy for prostatic carcinoma. J Urol. 1995; 153(6): 1866–1869.
    PubMed
  193. Hautmann RE, Sauter TW, Wenderoth UK. Radical retropubic prostatectomy: morbidity and urinary continence in 418 consecutive cases. Urology. 1994; 43(2 Suppl): 47–51.
    PubMed
  194. Leandri P, Rossignol G, Gautier JR, et al. Radical retropubic prostatectomy: morbidity and quality of life. Experience with 620 consecutive cases. J Urol. 1992; 147(3 Pt 2): 883–887.
    PubMed
  195. Pedersen KV, Herder A. Radical retropubic prostatectomy for localised prostatic carcinoma: a clinical and pathological study of 201 cases. Scand J Urol Nephrol. 1993; 27(2): 219–224.
    PubMed
  196. Shekarriz B, Upadhyay J, Wood DP. Intraoperative, perioperative, and long-term complications of radical prostatectomy. Urol Clin North Am. 2001; 28(3): 639–653.
    PubMed
  197. Andriole GL, Smith DS, Rao G, et al. Early complications of contemporary anatomical radical retropubic prostatectomy. J Urol. 1994; 152(5 Pt 2): 1858–1860.
    PubMed
  198. Dillioglugil O, Leibman BD, Leibman NS, et al. Risk factors for complications and morbidity after radical retropubic prostatectomy. J Urol. 1997; 157(5): 1760–1767.
    PubMed
  199. Lerner SE, Blute ML, Lieber MM, et al. Morbidity of contemporary radical retropubic prostatectomy for localized prostate cancer. Oncology (Williston Park). 1995; 9(5): 379–385.
    PubMed
  200. Catalona WJ, Carvalhal GF, Mager DE, et al. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol. 1999; 162(2): 433–438.
    PubMed
  201. Hammond J, Kozma C, Hart JC, et al. Rates of venous thromboembolism among patients with major surgery for cancer. Ann Surg Oncol. 2011; 18(12): 3240–3247.
    CrossRefPubMed
  202. Kakkar V. The diagnosis of deep vein thrombosis using the 125 I fibrinogen test. Arch Surg. 1972; 104(2): 152–159.
    PubMed
  203. Beyer J, Wessela S, Hakenberg OW, et al. Incidence, risk profile and morphological pattern of venous thromboembolism after prostate cancer surgery. J Thromb Haemost. 2009; 7(4): 597–604.
    CrossRefPubMed
  204. Chan SYS, Leung VFY, Yee CH, et al. Incidence of postoperative deep vein thrombosis after robotic-assisted laparoscopic prostatectomy: a prospective study in Chinese patients. Int Urol Nephrol. 2014; 46(11): 2139–2142.
    CrossRefPubMed
  205. Sawczuk IS, Williams D, Chang DT. Low molecular weight heparin for venous thromboembolism prophylaxis in urologic oncologic surgery. Cancer Invest. 2002; 20(7-8): 889–892.
    PubMed
  206. Kibel AS, Loughlin KR. Pathogenesis and prophylaxis of postoperative thromboembolic disease in urological pelvic surgery. J Urol. 1995; 153(6): 1763–1774.
    PubMed
  207. Potretzke AM, Wong KS, Shi F, et al. Highest risk of symptomatic venous thromboembolic events after radical cystectomy occurs in patients with obesity or nonurothelial cancers. Urol Ann. 2015; 7(3): 355–360.
    CrossRefPubMed
  208. O'Farrell S, Sandström K, Garmo H, et al. Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy. BJU Int. 2016; 118(3): 391–398.
    CrossRefPubMed
  209. Pettus JA, Eggener SE, Shabsigh A, et al. Perioperative clinical thromboembolic events after radical or partial nephrectomy. Urology. 2006; 68(5): 988–992.
    CrossRefPubMed
  210. Smith AB, Horvath-Puhó E, Nielsen ME, et al. Effect of comorbidity on risk of venous thromboembolism in patients with renal cell carcinoma. Urol Oncol. 2014; 32(4): 466–472.
    CrossRefPubMed
  211. Ihaddadene R, Yokom DW, Le Gal G, et al. The risk of venous thromboembolism in renal cell carcinoma patients with residual tumor thrombus. J Thromb Haemost. 2014; 12(6): 855–859.
    CrossRefPubMed
  212. Yokom DW, Ihaddadene R, Moretto P, et al. Increased risk of preoperative venous thromboembolism in patients with renal cell carcinoma and tumor thrombus. J Thromb Haemost. 2014; 12(2): 169–171.
    CrossRefPubMed
  213. Kavoussi LR, Sosa E, Chandhoke P, et al. Complications of laparoscopic pelvic lymph node dissection. J Urol. 1993; 149(2): 322–325.
    PubMed
  214. Cadeddu JA, Wolfe JS, Nakada S, et al. Complications of laparoscopic procedures after concentrated training in urological laparoscopy. J Urol. 2001; 166(6): 2109–2111.
    PubMed
  215. Fahlenkamp D, Rassweiler J, Fornara P, et al. Complications of laparoscopic procedures in urology: experience with 2,407 procedures at 4 German centers. J Urol. 1999; 162(3 Pt 1): 765–770.
    PubMed
  216. Rassweiler JJ, Seemann O, Frede T, et al. Retroperitoneoscopy: experience with 200 cases. J Urol. 1998; 160(4): 1265–1269.
    PubMed
  217. TRABULSI E, GUILLONNEAU B. LAPAROSCOPIC RADICAL PROSTATECTOMY. The Journal of Urology. 2005; 173(4): 1072–1079.
    CrossRef
  218. Montgomery JS, Wolf JS. Venous thrombosis prophylaxis for urological laparoscopy: fractionated heparin versus sequential compression devices. J Urol. 2005; 173(5): 1623–1626.
    CrossRefPubMed
  219. Permpongkosol S, Link RE, Su LM, et al. Complications of 2,775 urological laparoscopic procedures: 1993 to 2005. J Urol. 2007; 177(2): 580–585.
    CrossRefPubMed
  220. Secin FP, Jiborn T, Bjartell AS, et al. Multi-institutional study of symptomatic deep venous thrombosis and pulmonary embolism in prostate cancer patients undergoing laparoscopic or robot-assisted laparoscopic radical prostatectomy. Eur Urol. 2008; 53(1): 134–145.
    CrossRefPubMed
  221. Chalmers DJ, Scarpato KR, Staff I, et al. Does heparin prophylaxis reduce the risk of venous thromboembolism in patients undergoing robot-assisted prostatectomy? J Endourol. 2013; 27(6): 800–803.
    CrossRefPubMed
  222. Patel T, Kirby W, Hruby G, et al. Heparin prophylaxis and the risk of venous thromboembolism after robotic-assisted laparoscopic prostatectomy. BJU Int. 2011; 108(5): 729–732.
    CrossRefPubMed
  223. Abel EJ, Wong K, Sado M, et al. Surgical operative time increases the risk of deep venous thrombosis and pulmonary embolism in robotic prostatectomy. JSLS. 2014; 18(2): 282–287.
    CrossRefPubMed
  224. Donat R, Mancey-Jones B. Incidence of thromboembolism after transurethral resection of the prostate (TURP)--a study on TED stocking prophylaxis and literature review. Scand J Urol Nephrol. 2002; 36(2): 119–123.
    CrossRefPubMed
  225. Tikkinen KAO, Agarwal A, Craigie S, et al. Systematic reviews of observational studies of risk of thrombosis and bleeding in urological surgery (ROTBUS): introduction and methodology. Syst Rev. 2014; 3: 150.
    CrossRefPubMed
  226. Kutnowski M, Vandendris M, Steinberger R, et al. Prevention of postoperative deep-vein thrombosis by low-dose heparin in urological surgery. A double-blind, randomised study. Urol Res. 1977; 5(3): 123–125.
    PubMed
  227. Sebeseri O, Kummer H, Zingg E. Controlled prevention of post-operative thrombosis in urological diseases with depot heparin. Eur Urol. 1975; 1(5): 229–230.
    PubMed
  228. Bigg SW, Catalona WJ. Prophylactic mini-dose heparin in patients undergoing radical retropubic prostatectomy. A prospective trial. Urology. 1992; 39(4): 309–313.
    PubMed
  229. Vandendris M, Kutnowski M, Futeral B, et al. Prevention of postoperative deep-vein thrombosis by low-dose heparin in open prostatectomy. Urol Res. 1980; 8(4): 219–221.
    PubMed
  230. Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988; 318(18): 1162–1173.
    CrossRefPubMed
  231. Le Ga, Steg A, Le Gu. imag Subcutaneous enoxaparine (Lovenox) versus placebo for preventing deep vein thrombosis (DVT) after transurethral prostatectomy (TUP). Thromb Haemost. 1987; 58: 116.
  232. Sawczuk IS, Williams D, Chang DT. Low molecular weight heparin for venous thromboembolism prophylaxis in urologic oncologic surgery. Cancer Invest. 2002; 20(7-8): 889–892.
    PubMed
  233. Koch MO, Jr JAS. Low molecular weight heparin and radical prostatectomy: a prospective analysis of safety and side effects. Prostate Cancer Prostatic Dis. 1997; 1(2): 101–104.
    CrossRefPubMed
  234. Koonce J, Selikowitz S, McDougal WS. Complications of low-dose heparin prophylaxis following pelvic lymphadenectomy. Urology. 1986; 28(1): 21–25.
    PubMed
  235. Tomic R, Granfors T, Sjödin JG, et al. Lymph leakage after staging pelvic lymphadenectomy for prostatic carcinoma with and without heparin prophylaxis. Scand J Urol Nephrol. 1994; 28(3): 273–275.
    PubMed
  236. Musch M, Klevecka V, Roggenbuck U, et al. Complications of pelvic lymphadenectomy in 1,380 patients undergoing radical retropubic prostatectomy between 1993 and 2006. J Urol. 2008; 179(3): 923–928.
    CrossRefPubMed
  237. Khoder WY, Trottmann M, Buchner A, et al. Risk factors for pelvic lymphoceles post-radical prostatectomy. Int J Urol. 2011; 18(9): 638–643.
    CrossRefPubMed
  238. Sieber PR, Rommel FM, Agusta VE, et al. Is heparin contraindicated in pelvic lymphadenectomy and radical prostatectomy? J Urol. 1997; 158(3 Pt 1): 869–871.
    PubMed
  239. Nakamura K, Kasraeian A, Yacoub S, et al. The use of enoxaparin to prevent venous thromboembolism in patients undergoing radical retropubic prostatectomy: feasibility and utility. Int Braz J Urol. 2007; 33(3): 347–352.
    PubMed
  240. Grasso M, Confalonieri S, Blanco S, et al. Preoperative blood donation program and postoperative low molecular weight heparine (LMWH) prophylaxis in patients undergoing radical prostatectomy. Arch Esp Urol. 2009; 62(2): 161–166.
    PubMed
  241. Donat R, Mancey-Jones B. Incidence of thromboembolism after transurethral resection of the prostate (TURP)--a study on TED stocking prophylaxis and literature review. Scand J Urol Nephrol. 2002; 36(2): 119–123.
    CrossRefPubMed
  242. Scarpa RM, Carrieri G, Gussoni G, et al. @RISTOS Study Group. Clinically overt venous thromboembolism after urologic cancer surgery: results from the @RISTOS Study. Eur Urol. 2007; 51(1): 130–136.
    CrossRefPubMed
  243. Cerruto MA, D'Elia C, Piccoli M, et al. Association between postoperative thromboembolism prophylaxis and complications following urological surgery. Exp Ther Med. 2016; 11(1): 157–163.
    CrossRefPubMed
  244. Coe NP, Collins RE, Klein LA, et al. Prevention of deep vein thrombosis in urological patients: a controlled, randomized trial of low-dose heparin and external pneumatic compression boots. Surgery. 1978; 83(2): 230–234.
    PubMed
  245. Koya MP, Manoharan M, Kim SS, et al. Venous thromboembolism in radical prostatectomy: is heparinoid prophylaxis warranted? BJU Int. 2005; 96(7): 1019–1021.
    CrossRefPubMed
  246. Cisek LJ, Walsh PC. Thromboembolic complications following radical retropubic prostatectomy. Influence of external sequential pneumatic compression devices. Urology. 1993; 42(4): 406–408.
    PubMed
  247. Cindolo L, Salzano L, Mirone V, et al. Thromboprophylaxis in radical retropubic prostatectomy: efficacy and patient compliance of a dual modality. Urol Int. 2009; 83(1): 12–18.
    CrossRefPubMed
  248. Coe NP, Collins RE, Klein LA, et al. Prevention of deep vein thrombosis in urological patients: a controlled, randomized trial of low-dose heparin and external pneumatic compression boots. Surgery. 1978; 83(2): 230–234.
    PubMed
  249. Hansberry KL, Thompson IM. Jr, Bauman J, Deppe S, Rodriguez FR A prospective comparison of thromboembolic stocking, external Sequential pneumatic compresssion stocking and heparin sodium/dihydroerotamine mesylate for the prevention of thromboembolic complications in urological surgery. J Urol. 1991; 145: 1205–1208.
  250. Montgomery JS, Wolf JS. Venous thrombosis prophylaxis for urological laparoscopy: fractionated heparin versus sequential compression devices. J Urol. 2005; 173(5): 1623–1626.
    CrossRefPubMed
  251. Alberts BD, Woldu SL, Weinberg AC, et al. Venous thromboembolism after major urologic oncology surgery: a focus on the incidence and timing of thromboembolic events after 27,455 operations. Urology. 2014; 84(4): 799–806.
    CrossRefPubMed
  252. VanDlac AA, Cowan NG, Chen Y, et al. Timing, incidence and risk factors for venous thromboembolism in patients undergoing radical cystectomy for malignancy: a case for extended duration pharmacological prophylaxis. J Urol. 2014; 191(4): 943–947.
    CrossRefPubMed
  253. Kukreja JE, Levey HR, Scosyrev E, et al. Effectiveness and safety of extended-duration prophylaxis for venous thromboembolism in major urologic oncology surgery. Urol Oncol. 2015; 33(9): 387.e7–387.16.
    CrossRefPubMed
  254. Kahn SR, Lim W, Dunn AS, et al. American College of Chest Physicians. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): e195S–e226S.
    CrossRefPubMed
  255. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999; 341(11): 793–800.
    CrossRefPubMed
  256. Leizorovicz A, Cohen AT, Turpie AGG, et al. PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004; 110(7): 874–879.
    CrossRefPubMed
  257. Cohen AT, Davidson BL, Gallus AS, et al. ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006; 332(7537): 325–329.
    CrossRefPubMed
  258. Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thromb Haemost. 1996; 76(4): 529–534.
    PubMed
  259. Harenberg J, Roebruck P, Heene DL. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group. Haemostasis. 1996; 26(3): 127–139.
    PubMed
  260. Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Haemostasis. 1996; 26 Suppl 2: 49–56.
    PubMed
  261. Kleber FX, Witt C, Vogel G, et al. THE-PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J. 2003; 145(4): 614–621.
    CrossRefPubMed
  262. Schellong SM, Haas S, Greinacher A, et al. An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opin Pharmacother. 2010; 11(18): 2953–2961.
    CrossRefPubMed
  263. Riess H, Haas S, Tebbe U, et al. A randomized, double-blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non-surgical patients: CERTIFY Study. J Thromb Haemost. 2010; 8(6): 1209–1215.
    CrossRefPubMed
  264. Akl EA, Vasireddi SR, Gunukula S, et al. Anticoagulation for patients with cancer and central venous catheters. Cochrane Database Syst Rev. 2011(2): CD006468.
    CrossRefPubMed
  265. Goldhaber SZ. Risk factors for venous thromboembolism. J Am Coll Cardiol. 2010; 56(1): 1–7.
    CrossRefPubMed
  266. Timp JF, Braekkan SK, Versteeg HH, et al. Epidemiology of cancer-associated venous thrombosis. Blood. 2013; 122(10): 1712–1723.
    CrossRefPubMed
  267. Walker AJ, West J, Card TR, et al. Variation in the risk of venous thromboembolism in people with colorectal cancer: a population-based cohort study from England. J Thromb Haemost. 2014; 12(5): 641–649.
    PubMed
  268. Streiff MB. Association between cancer types, cancer treatments, and venous thromboembolism in medical oncology patients. Clin Adv Hematol Oncol. 2013; 11(6): 349–357.
    PubMed
  269. Sood SL. Cancer-associated thrombosis. Curr Opin Hematol. 2009; 16(5): 378–385.
    CrossRefPubMed
  270. Roselli M, Ferroni P, Riondino S, et al. Impact of chemotherapy on activated protein C-dependent thrombin generation--association with VTE occurrence. Int J Cancer. 2013; 133(5): 1253–1258.
    CrossRefPubMed
  271. Falanga A, Marchetti M. Anticancer treatment and thrombosis. Thromb Res. 2012; 129(3): 353–359.
    CrossRefPubMed
  272. Deitcher SR, Gomes MPV. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer. 2004; 101(3): 439–449.
    CrossRefPubMed
  273. Perry JR. Anticoagulation of malignant glioma patients in the era of novel antiangiogenic agents. Curr Opin Neurol. 2010; 23(6): 592–596.
    CrossRefPubMed
  274. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111(10): 4902–4907.
    CrossRefPubMed
  275. Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010; 116(24): 5377–5382.
    CrossRefPubMed
  276. Ben-Aharon I, Stemmer SM, Leibovici L, et al. Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies - systematic review and meta-analysis. Acta Oncol. 2014; 53(9): 1230–1237.
    CrossRefPubMed
  277. Agnelli G, Gussoni G, Bianchini C, et al. PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009; 10(10): 943–949.
    CrossRefPubMed
  278. Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 2004; 126(5): 715–721.
    CrossRefPubMed
  279. De Stefano V, Za T, Rossi E. Venous thromboembolism in multiple myeloma. Semin Thromb Hemost. 2014; 40(3): 338–347.
    CrossRefPubMed
  280. Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011; 29(8): 986–993.
    CrossRefPubMed
  281. Hicks LK, Haynes AE, Reece DE, et al. Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-based Care. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev. 2008; 34(5): 442–452.
    CrossRefPubMed
  282. Maraveyas A, Waters J, Roy R, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer. 2012; 48(9): 1283–1292.
    CrossRefPubMed
  283. Haas SK, Freund M, Heigener D, et al. TOPIC Investigators. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost. 2012; 18(2): 159–165.
    CrossRefPubMed
  284. Agnelli G, Gussoni G, Bianchini C, et al. PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009; 10(10): 943–949.
    CrossRefPubMed
  285. Perry JR, Julian JA, Laperriere NJ, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost. 2010; 8(9): 1959–1965.
    CrossRefPubMed
  286. Verso M, Gussoni G, Agnelli G. Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC-2 studies. J Thromb Haemost. 2010; 8(7): 1649–1651.
    CrossRefPubMed
  287. Riess H, Pelzer U, Opitz B, et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. Journal of Clinical Oncology. 2010; 28(15_suppl): 4033–4033.
    CrossRef
  288. Di Nisio M, Porreca E, Otten HM, et al. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2014(8): CD008500.
    CrossRefPubMed
  289. Che DH, Cao JY, Shang LH, et al. The efficacy and safety of low-molecular-weight heparin use for cancer treatment: a meta-analysis. Eur J Intern Med. 2013; 24(5): 433–439.
    CrossRefPubMed
  290. Akl EA, Kahale LA, Ballout RA, et al. Parenteral anticoagulation in ambulatory patients with cancer. Cochrane Database Syst Rev. 2014(12): CD006652.
    CrossRefPubMed
  291. Hull RD, Schellong SM, Tapson VF, et al. EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010; 153(1): 8–18.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note